| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04278404 |
| P767 | contributor to the creative work or subject | Eunice Kennedy Shriver National Institute of Child Health and Human Development | Q5409765 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2024-04-24 | |
| P4135 | maximum age | 20 | |
| P1050 | medical condition | pneumonia | Q12192 |
| arterial hypertension | Q41861 | ||
| hypokalemia | Q794086 | ||
| bronchopulmonary dysplasia | Q922640 | ||
| hyperaldosteronism | Q1640860 | ||
| adrenal insufficiency | Q2507454 | ||
| P2899 | minimum age | 2 | |
| P1132 | number of participants | 5000 | |
| P4844 | research intervention | aminocaproic acid | Q255968 |
| tranexamic acid | Q418666 | ||
| sevelamer | Q904153 | ||
| dextroamphetamine | Q1706418 | ||
| amphetamines | Q2445303 | ||
| P1813 | short name | POPS or POP02 | |
| P859 | sponsor | Duke University | Q168751 |
| P580 | start time | 2020-02-24 | |
| P8363 | study type | observational study | Q818574 |
| P1476 | title | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs |